Scott Zamvil, PhD, MD

Neurologist

Dr. Scott Zamvil is a neurologist and immunologist who specializes in treating multiple sclerosis and neuromyelitis optica. His research focuses on developing novel treatments for these autoimmune diseases.

Zamvil earned his medical degree and a doctorate in microbiology and immunology from Stanford University. He then completed a residency in internal medicine at Stanford University and a residency in neurology at Brigham and Women's Hospital. Before coming to UCSF, he was a neurologist at Brigham and Women's Hospital.

Zamvil is a board member of the International Society of Neuroimmunology. He is also an advisor for America's Committee for Treatment and Research in Multiple Sclerosis. Zamvil serves as deputy editor of the journal Neurology: Neuroimmunology & Neuroinflammation. He is a professor of neurology at UCSF.

Clinics

Multiple Sclerosis Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2069
Fax: (415) 353-2633

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Board Certification

Neurology, American Board of Psychiatry and Neurology

Academic Title

Professor

More about Scott Zamvil

Education

Stanford University School of Medicine 1988

Residencies

Stanford University, Ph.D., Medical Microbiology 1986
Stanford University School of Medicine, Internal Medicine 1990
Brigham and Women's Hospital, Neurology 1993

Selected Research and Publications

  1. Prod'homme T, Zamvil SS. The Evolving Mechanisms of Action of Glatiramer Acetate. Cold Spring Harb Perspect Med. 2018 Feb 12.
  2. Wang Q, He Z, Huang M, Liu T, Wang Y, Xu H, Duan H, Ma P, Zhang L, Zamvil SS, Hidalgo J, Zhang Z, O'Rourke DM, Dahmane N, Brem S, Mou Y, Gong Y, Fan Y. Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2a. Nat Commun. 2018 Feb 08; 9(1):559.
  3. Sabatino JJ, Zamvil SS, Hauser SL. B-Cell Therapies in Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018 Jan 22.
  4. Zamvil SS, Spencer CM, Baranzini SE, Cree BAC. The Gut Microbiome in Neuromyelitis Optica. Neurotherapeutics. 2018 Jan; 15(1):92-101.
  5. Sagan SA, Cruz-Herranz A, Spencer CM, Ho PP, Steinman L, Green AJ, Sobel RA, Zamvil SS. Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4. J Vis Exp. 2017 Aug 21; (126).
  6. Sabatino JJ, Zamvil SS. Aryl hydrocarbon receptor activity may serve as a surrogate marker for MS disease activity. Neurol Neuroimmunol Neuroinflamm. 2017 Jul; 4(4):e366.
  7. Sabatino JJ, Mehta NJ, Kakar S, Zamvil SS, Cree BAC. Acute liver injury in a Glatopa-treated patient with MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jul; 4(4):e368.
  8. Lehmann-Horn K, Wang SZ, Sagan SA, Zamvil SS, von Büdingen HC. B cell repertoire expansion occurs in meningeal ectopic lymphoid tissue. JCI Insight. 2016 Dec 08; 1(20):e87234.
  9. Sagan SA, Winger RC, Cruz-Herranz A, Nelson PA, Hagberg S, Miller CN, Spencer CM, Ho PP, Bennett JL, Levy M, Levin MH, Verkman AS, Steinman L, Green AJ, Anderson MS, Sobel RA, Zamvil SS. Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4. Proc Natl Acad Sci U S A. 2016 12 20; 113(51):14781-14786.
  10. Mei F, Lehmann-Horn K, Shen YA, Rankin KA, Stebbins KJ, Lorrain DS, Pekarek K, A Sagan S, Xiao L, Teuscher C, von Büdingen HC, Wess J, Lawrence JJ, Green AJ, Fancy SP, Zamvil SS, Chan JR. Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. Elife. 2016 Sep 27; 5.
  11. Tremlett H, Fadrosh DW, Faruqi AA, Hart J, Roalstad S, Graves J, Spencer CM, Lynch SV, Zamvil SS, Waubant E. Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls. BMC Neurol. 2016 Sep 21; 16(1):182.
  12. Varrin-Doyer M, Pekarek KL, Spencer CM, Bernard CC, Sobel RA, Cree BA, Schulze-Topphoff U, Zamvil SS. Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression. Neurol Neuroimmunol Neuroinflamm. 2016 Oct; 3(5):e272.
  13. Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Yeaman MR, Smith TJ. Restoring immune tolerance in neuromyelitis optica: Part I. Neurol Neuroimmunol Neuroinflamm. 2016 Oct; 3(5):e276.
  14. Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Smith TJ, Yeaman MR. Restoring immune tolerance in neuromyelitis optica: Part II. Neurol Neuroimmunol Neuroinflamm. 2016 Oct; 3(5):e277.
  15. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016 Oct; 80(4):499-510.
  16. Cree BA, Spencer CM, Varrin-Doyer M, Baranzini SE, Zamvil SS. Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens. Ann Neurol. 2016 Sep; 80(3):443-7.
  17. Winger RC, Zamvil SS. Your nose knows how to target brain inflammation. Brain. 2016 07; 139(Pt 7):1866-9.
  18. Winger RC, Zamvil SS. Antibodies in multiple sclerosis oligoclonal bands target debris. Proc Natl Acad Sci U S A. 2016 07 12; 113(28):7696-8.
  19. Steinman L, Zamvil SS. Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis. Curr Opin Neurol. 2016 06; 29(3):340-4.
  20. Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, Spencer CM, Shetty A, Sagan SA, Cree BA, Sobel RA, Wipke BT, Steinman L, Scannevin RH, Zamvil SS. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci U S A. 2016 Apr 26; 113(17):4777-82.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.